MX2015015355A - Tratamiento de enfermedades miopaticas y neurodegenerativas por agregacion de proteina mediante administracion parenteral. - Google Patents
Tratamiento de enfermedades miopaticas y neurodegenerativas por agregacion de proteina mediante administracion parenteral.Info
- Publication number
- MX2015015355A MX2015015355A MX2015015355A MX2015015355A MX2015015355A MX 2015015355 A MX2015015355 A MX 2015015355A MX 2015015355 A MX2015015355 A MX 2015015355A MX 2015015355 A MX2015015355 A MX 2015015355A MX 2015015355 A MX2015015355 A MX 2015015355A
- Authority
- MX
- Mexico
- Prior art keywords
- trehalose
- treatment
- protein aggregation
- myopathic
- parenteral administration
- Prior art date
Links
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 title abstract 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 title abstract 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 title abstract 3
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 238000007911 parenteral administration Methods 0.000 title 1
- 230000004845 protein aggregation Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000004849 abnormal protein aggregation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361820278P | 2013-05-07 | 2013-05-07 | |
| PCT/IL2014/050411 WO2014181333A2 (en) | 2013-05-07 | 2014-05-07 | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015015355A true MX2015015355A (es) | 2016-07-18 |
Family
ID=51022384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015355A MX2015015355A (es) | 2013-05-07 | 2014-05-07 | Tratamiento de enfermedades miopaticas y neurodegenerativas por agregacion de proteina mediante administracion parenteral. |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US10493023B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2994145B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6837835B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160009617A (cg-RX-API-DMAC7.html) |
| AU (5) | AU2014264228A1 (cg-RX-API-DMAC7.html) |
| CA (3) | CA3239805A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR20150637A (cg-RX-API-DMAC7.html) |
| EA (1) | EA201501054A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL241757B (cg-RX-API-DMAC7.html) |
| MD (1) | MD20150120A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015015355A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20160012A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201509030TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014181333A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014181333A2 (en) | 2013-05-07 | 2014-11-13 | Bio Blast Pharma Ltd. | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose |
| US9084720B2 (en) * | 2013-05-07 | 2015-07-21 | BioBlast Pharma Ltd. | Compositions and methods for treating oculopharyngeal muscular dystrophy |
| CA3012502A1 (en) * | 2016-02-08 | 2017-08-17 | Junaxo, Inc. | Use of trehalose for treatment of neurological diseases |
| US10512656B2 (en) | 2016-04-21 | 2019-12-24 | Baylor College Of Medicine | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| WO2019143685A1 (en) | 2018-01-16 | 2019-07-25 | Women & Infants Hospital Of Rhode Island | Methods and compositions for treating pre-eclampsia |
| CA3150309A1 (en) | 2019-10-01 | 2021-04-08 | Seelos Therapeutics, Inc. | Trehalose formulations and uses thereof |
| EP4741013A3 (en) * | 2020-02-13 | 2026-08-05 | Prilenia Neurotherapeutics Ltd. | Combination therapy for treating amyotrophic lateral sclerosis using pridopidine and another active agent |
| WO2022013940A1 (ja) | 2020-07-14 | 2022-01-20 | オリンパス株式会社 | 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体 |
| CN116966192A (zh) * | 2022-09-26 | 2023-10-31 | 西安文理学院 | 海藻糖在制备sca3疾病治疗药物中的应用 |
| AU2023403437A1 (en) * | 2022-11-30 | 2025-06-19 | GLD Debt Acquisition 2025-1, Inc. | Trehalose for treating huntington's disease |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3782404A (en) | 1972-06-14 | 1974-01-01 | Commercial Shearing | Adjustable, metered, directional flow control arrangements |
| JPS4950521U (cg-RX-API-DMAC7.html) | 1972-08-14 | 1974-05-02 | ||
| JPS516109B2 (cg-RX-API-DMAC7.html) | 1972-12-28 | 1976-02-25 | ||
| JPS557829Y2 (cg-RX-API-DMAC7.html) | 1974-07-01 | 1980-02-21 | ||
| JPS516109A (en) | 1974-07-05 | 1976-01-19 | Toshiba Tungaloy Co Ltd | Aruminaatankachitan chitsukachitankeishoketsugokin |
| JP4033510B2 (ja) | 1995-12-27 | 2008-01-16 | ロート製薬株式会社 | トレハロースを含有する眼科用医薬組成物 |
| AU1172097A (en) | 1995-12-27 | 1997-07-28 | Rohto Pharmaceutical Co., Ltd. | Pharmaceutical composition containing trehalose |
| JP3455633B2 (ja) | 1996-06-28 | 2003-10-14 | 味の素ファルマ株式会社 | 潰瘍性大腸炎の予防又は治療剤 |
| US6440446B1 (en) | 1998-04-22 | 2002-08-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Agent for anti-osteoporosis |
| US6602865B1 (en) | 1998-11-16 | 2003-08-05 | Ivax Drug Research Institute, Ltd. | Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds |
| JP2001302517A (ja) * | 2000-04-24 | 2001-10-31 | Tokyo Univ Of Pharmacy & Life Science | 脳浮腫の予防治療薬 |
| CA2355814C (en) | 2000-09-14 | 2010-06-29 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Pharmaceutical composition for ophthalmic use |
| JP4754066B2 (ja) | 2000-12-22 | 2011-08-24 | 株式会社林原生物化学研究所 | 抗関節障害剤 |
| JP4255101B2 (ja) | 2002-03-15 | 2009-04-15 | 独立行政法人理化学研究所 | 神経変性疾患の治療薬 |
| WO2004060343A1 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Antibody-containing particles and compositions |
| EP1600143B1 (en) | 2003-02-13 | 2019-07-10 | Hayashibara Co., Ltd. | SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE |
| US20050215562A1 (en) * | 2003-06-23 | 2005-09-29 | Patrick Tremblay | Methods for treating protein aggregation disorders |
| US20050100637A1 (en) | 2003-11-12 | 2005-05-12 | Robert Murray | Carbohydrate and electrolyte replacement composition |
| US20060099567A1 (en) * | 2004-04-08 | 2006-05-11 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
| US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| EP1888095A4 (en) | 2005-05-13 | 2009-08-26 | Whitehead Biomedical Inst | MODULATORS OF ALPHA-SYNUCLEIN INDUCED TOXICITY |
| MY142987A (en) | 2005-06-08 | 2011-02-14 | Hayashibara Biochem Lab | Solution for tissue adhesion prevention and method for tissue adhesion prevention |
| JP2006342108A (ja) * | 2005-06-09 | 2006-12-21 | Mitsubishi Chemicals Corp | アミロスフェロイドにより発生する疾患の予防治療剤 |
| CN102266274B (zh) | 2005-08-11 | 2016-05-18 | 株式会社林原 | 胶原产生增强剂及其用途 |
| EP1958612B1 (en) | 2005-11-30 | 2014-07-02 | The Nisshin OilliO Group, Ltd. | Trehalose fatty acid ester composition |
| JP4950521B2 (ja) | 2006-03-08 | 2012-06-13 | 公益財団法人野口研究所 | トレハロース誘導体とその製造法 |
| CN101443344B (zh) | 2006-03-27 | 2012-08-29 | 大塚化学株式会社 | 海藻糖化合物及含有该化合物的药物 |
| CN101091713A (zh) * | 2006-06-19 | 2007-12-26 | 深圳市牌牌科技有限公司 | 预防和治疗神经损伤类疾病雷公藤红素胶囊及其制备方法和用法 |
| CN100571707C (zh) | 2006-07-24 | 2009-12-23 | 凌沛学 | 含有海藻糖的关节腔内注射给药制剂 |
| JP5258582B2 (ja) | 2007-01-31 | 2013-08-07 | 株式会社糖鎖工学研究所 | トレハロース化合物、その製造方法、及び該化合物を含有する免疫賦活剤 |
| EP2198869B1 (en) * | 2007-02-23 | 2015-09-16 | Next 21 K.K. | Trehalose for the treatment or prevention of vasospasm |
| TW200848063A (en) | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| EA201070544A1 (ru) * | 2007-10-31 | 2010-12-30 | Диффьюжн Фармасьютикалз Ллс | Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений |
| JP2009249292A (ja) * | 2008-04-01 | 2009-10-29 | Toray Ind Inc | ポリリン酸を安定化剤とするエリスロポエチン溶液製剤 |
| US20110142799A1 (en) * | 2008-06-23 | 2011-06-16 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
| KR101021078B1 (ko) * | 2008-07-22 | 2011-03-14 | 포항공과대학교 산학협력단 | 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물 |
| WO2010050178A1 (ja) | 2008-10-31 | 2010-05-06 | 大塚化学株式会社 | トレハロース化合物、その製造方法、及び該化合物を含有する医薬 |
| WO2010056804A1 (en) * | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
| EP3689346B1 (en) | 2008-12-10 | 2024-01-24 | WisTa Laboratories Ltd. | 3,6-disubstituted xanthylium salts for treating tauopathies |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| WO2011017070A1 (en) * | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| WO2011108762A1 (ja) | 2010-03-05 | 2011-09-09 | 株式会社林原生物化学研究所 | インスリン抵抗性の予防及び/又は改善剤 |
| KR20130043165A (ko) | 2010-06-25 | 2013-04-29 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
| CN101914118B (zh) | 2010-08-06 | 2012-07-04 | 山东大学 | 海藻糖衍生物及其制备方法与应用 |
| EP2637652A2 (en) * | 2010-11-10 | 2013-09-18 | Katholieke Universiteit Leuven | Osteoclast activity |
| US9186356B2 (en) | 2011-01-08 | 2015-11-17 | Academia Sinica | Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) |
| ES2664844T3 (es) | 2011-06-20 | 2018-04-23 | Mount Sinai School Of Medicine | Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos |
| US8623839B2 (en) * | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
| US20130310467A1 (en) | 2012-03-06 | 2013-11-21 | The Nisshin Oillio Group, Ltd. | Trehalose fatty acid ester composition |
| JP5432322B2 (ja) | 2012-05-08 | 2014-03-05 | 株式会社大塚製薬工場 | トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液 |
| US20130312784A1 (en) | 2012-05-24 | 2013-11-28 | For Your Ease Only, Inc. | Cosmetic organizer |
| US20140032304A1 (en) | 2012-07-27 | 2014-01-30 | Google Inc. | Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal |
| JP2014139160A (ja) | 2012-12-21 | 2014-07-31 | Masaaki Hayashibara | 脳機能改善剤及び脳機能改善用食品 |
| WO2014181333A2 (en) | 2013-05-07 | 2014-11-13 | Bio Blast Pharma Ltd. | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose |
| US9084720B2 (en) | 2013-05-07 | 2015-07-21 | BioBlast Pharma Ltd. | Compositions and methods for treating oculopharyngeal muscular dystrophy |
| JP6130224B2 (ja) | 2013-05-27 | 2017-05-17 | 公益財団法人微生物化学研究会 | 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物 |
| TWI507197B (zh) | 2013-07-17 | 2015-11-11 | Univ Nat Taiwan Normal | 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途 |
| US10906981B2 (en) | 2013-07-19 | 2021-02-02 | The Regents Of The University Of California | Compositions and methods related to structures that cross the blood brain barrier |
| EP4026545A1 (en) | 2014-11-19 | 2022-07-13 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
| US20160303150A1 (en) | 2015-04-16 | 2016-10-20 | BioBlast Pharma Ltd. | Deuterated trehalose formulations and uses thereof |
| WO2017136533A1 (en) | 2016-02-03 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses |
| US10512656B2 (en) | 2016-04-21 | 2019-12-24 | Baylor College Of Medicine | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
| CA3150309A1 (en) | 2019-10-01 | 2021-04-08 | Seelos Therapeutics, Inc. | Trehalose formulations and uses thereof |
-
2014
- 2014-05-07 WO PCT/IL2014/050411 patent/WO2014181333A2/en not_active Ceased
- 2014-05-07 AU AU2014264228A patent/AU2014264228A1/en not_active Abandoned
- 2014-05-07 JP JP2016512480A patent/JP6837835B2/ja active Active
- 2014-05-07 CA CA3239805A patent/CA3239805A1/en active Pending
- 2014-05-07 KR KR1020157034700A patent/KR20160009617A/ko not_active Withdrawn
- 2014-05-07 MD MDA20150120A patent/MD20150120A2/ro not_active Application Discontinuation
- 2014-05-07 EP EP14733380.1A patent/EP2994145B1/en active Active
- 2014-05-07 MX MX2015015355A patent/MX2015015355A/es unknown
- 2014-05-07 EP EP22216238.0A patent/EP4218769A3/en active Pending
- 2014-05-07 EA EA201501054A patent/EA201501054A1/ru unknown
- 2014-05-07 CA CA2911399A patent/CA2911399C/en active Active
- 2014-05-07 CA CA3311794A patent/CA3311794A1/en active Pending
- 2014-05-07 SG SG11201509030TA patent/SG11201509030TA/en unknown
- 2014-05-07 PE PE2015002367A patent/PE20160012A1/es not_active Application Discontinuation
- 2014-05-07 US US14/889,727 patent/US10493023B2/en active Active
-
2015
- 2015-09-21 IL IL241757A patent/IL241757B/en active IP Right Grant
- 2015-12-04 CR CR20150637A patent/CR20150637A/es unknown
-
2019
- 2019-04-11 JP JP2019075517A patent/JP2019142907A/ja active Pending
- 2019-06-26 AU AU2019204513A patent/AU2019204513B2/en active Active
- 2019-07-02 US US16/460,046 patent/US10869831B2/en active Active
-
2020
- 2020-11-26 AU AU2020277197A patent/AU2020277197A1/en not_active Abandoned
-
2021
- 2021-06-08 JP JP2021095562A patent/JP2021152032A/ja active Pending
- 2021-06-23 US US17/355,607 patent/US20220117883A1/en not_active Abandoned
-
2023
- 2023-01-11 JP JP2023002536A patent/JP2023040211A/ja active Pending
- 2023-01-20 AU AU2023200303A patent/AU2023200303A1/en not_active Abandoned
- 2023-04-05 US US18/131,161 patent/US12239733B2/en active Active
-
2025
- 2025-01-30 US US19/041,077 patent/US20260014072A1/en active Pending
- 2025-03-07 JP JP2025036306A patent/JP2025087858A/ja active Pending
- 2025-03-13 AU AU2025201824A patent/AU2025201824A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014181333A3 (en) | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| BR112015027297A8 (pt) | administração local e concomitante de nanocarreadores sintéticos tolerogênicos para reduzir hipersensibilidade dos tipos i e iv | |
| PH12016500582A1 (en) | Heterocyclic compounds and uses thereof | |
| MX373851B (es) | Métodos de administración de tratamiento con pirfenidona. | |
| BR112015016930A2 (pt) | formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina | |
| BR112015027682A2 (pt) | Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente | |
| EP3141603A4 (en) | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| NZ714684A (en) | Stable oral solutions for combined api | |
| NZ702730A (en) | Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments | |
| EP2981258B8 (en) | Pharmaceutical formulations for subcutaneous administration of furosemide | |
| MX2015013091A (es) | Metodos mejorados de uso para secretoglobinas humanas recombinantes. | |
| MX382476B (es) | Dispersiones solidas de bendamustina e infusion continua. | |
| EA201890788A1 (ru) | Препараты оланзапина с замедленным высвобождением | |
| IL280952A (en) | Methods and drug compounds for the treatment of ophthalmic diseases | |
| GB2558494B (en) | Protein nanostructure based drug delivery system for the delivery of therapeutic agents to the anterior segment of the eye | |
| MX2019004736A (es) | Mini-tabletas de melatonina y metodos de fabricacion de las mismas. | |
| WO2014107737A3 (en) | Local delivery of il-17 inhibitors for treating ocular disease | |
| TW201613599A (en) | Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease | |
| MX2016010087A (es) | Filtros para equipos de infusion. | |
| BR112015013223A2 (pt) | composição farmacêutica | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| MX2015016678A (es) | Formulaciones farmaceuticas que comprenden agomelatina en forma de cocristal de agomelatina con un acido organico. | |
| AR102494A1 (es) | Métodos para tratar enfermedades oculares |